Welcome!

Anti-Cocaine Vaccine? Possible

Posted: November 29th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: | Comments Off on Anti-Cocaine Vaccine? Possible

An anti-cocaine vaccine combined with Immunovaccine‘s DepoVax showed promising results in an exploratory study. 


New Travel Agency Offers Trips to Alpine Destinations

Posted: November 28th, 2012 | Author: | Filed under: Sarasota-Bradenton Travel Professionals | Tags: | Comments Off on New Travel Agency Offers Trips to Alpine Destinations

Tom and Karen Niederer are a microcosm of the growing diversity of the Sarasota-Bradenton area.  Karen is originally from the UK and Tom is originally from Switzerland.  They lived in Austria for many years and now they live in Bradenton, FL.

Being experts on the Alpine countries of Europe – Germany, Switzerland, Italy, Liechtenstein and Austria – they decided to share the wonderful sites and experiences of this area with Americans.  They established a travel agency, Alpentouristik Travel, in 2009.  Their office is in Bradenton, on Lena Road, and they serve the entire Sarasota-Bradenton area.

Some of the tours they offer include a Three Countries Tour (Munich, Krimml Waterfalls, Berchtesgaden, Salzburg, Innsbruck, Venice and more) a European Splendor Tour (Austria, Italy, Liechtenstein and Switzerland) and a Historical Highlights Tour (Germany and Austria).  These tours are in May and June.  Of course, no Alpine travel agency would be complete without a ski tour!  Alpentouristik offers a trip to Saalbach-Hinterglemm, in the Austrian Alps, where visitors can find 124 miles of downhill slopes, 55 lifts, night skiing and lively nightlife in the village.  This trip is offered in March.

Alpentouristik Travel also offers tours through Central Europe and individually-tailored vacations in Austria.

Karen and Tom’s expertise comes from their 50 years of combined experience living and travelling through the Alpine countries of Europe.  When choosing a destination for your next trip, you definitely want to consult with these experts on Alpine travel.  They can be contacted via telephone at (941) 932-3144.

Please enjoy some photos of the sights of Central Europe.

 


Bird Flu Vaccine Being Tested on Humans

Posted: November 27th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , | Comments Off on Bird Flu Vaccine Being Tested on Humans

A total of 666 healthy adults ages 18 to 49 were enrolled in the two trials to demonstrate the immunogenicity of Novavax’s VLP-based H5N1 vaccine candidate at varying dose levels, with and without an adjuvant.  Each person received intramuscular injections of vaccine or placebo at day 0 and day 21, and will be followed for 13 months.  Current data show safety and immune responses over the first 42 days.

“We have demonstrated that Novavax can produce antigens from avian influenza strains that are as, or more, immunogenic than any other described in published results to date,” Stanley C. Erck, president and CEO of Novavax, said in a press release. “Importantly, as we accelerate our development activities, these results give us tremendous flexibility for pursuing pandemic vaccine products, including vaccines directed at population segments that are sensitive to adjuvant use.”

The U.S.government maintains a stockpile of similar vaccines, Gregory Wade, an analyst at Wedbush Securities, said. He expects there would be an annual stock of Novavax’s. The time frame for licensing the drug is 2015, he told Bloomberg, and the need is based on whether a strain of the virus breaks out.


Stronger Influenza Vaccines Needed

Posted: November 22nd, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , | Comments Off on Stronger Influenza Vaccines Needed

Researchers at the University of Minnesota’s Center for Infectious Disease Research and Policy claim current influenza vaccines offer less protection against the infectious disease than previously thought, and better ones are necessary.

A report titled “The Compelling Need for Game-Changing Influenza Vaccines” says the U.S.-licensed trivalent inactivated influenza vaccine does not differ widely from the one first developed in 1968. And a live-attenuated influenza vaccine licensed in 2003 is made using techniques from the 1930s, Fox reports.

So why hasn’t a new flu vaccine come along? The financial risks and inadequate incentives throw up roadblocks for most biotechs that might otherwise show interest. The entire process–from preclinical research through licensure–can take up to 15 years and cost more than $1 billion, the report says. A novel flu vaccine providing protection over the course of several years will need to cost more per dose than current vaccines for investors and manufacturers to realize the financial benefit of the endeavor.

And many believe the current flu vaccines offer enough protection. “A major barrier to the development of game-changing influenza vaccines is the perception that current vaccines are already highly effective in preventing influenza infection,” the report says.

Currently, 6 companies are licensed to produce and distribute flu vaccines in the U.S.: CSL, GlaxoSmithKline ($GSK), ID Biomedical, AstraZeneca’s MedImmune, Novartis  and Sanofi Pasteur. This year, a total of 135 million doses of influenza vaccine will be on hand. Each year, between 3,000 and 49,000 Americans die from seasonal influenza.


American Vaccine Manufacturer Applies to Buy Russian Pharma

Posted: November 20th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , | Comments Off on American Vaccine Manufacturer Applies to Buy Russian Pharma

Pharma giant Abbott Laboratories has filed an application to acquire Russia’s Petrovax Pharm, its flu vaccines partner. Such a deal would become one of the top three largest in the history of the Russian pharmaceutical market, experts say.

A team of Russian flu vaccine researchers founded Petrovax in 1996. Last year, the company’s sales hit $98 million, Izvestia reports, placing the company 12th among domestic pharma companies. Both companies declined to comment on the deal.

But Izvestia‘s sources say Abbott filed for approval to acquire 62.5% of Petrovax. This includes the 25% stake the European Bank for Reconstruction and Development acquired for $27 million in 2008, the 18.77% stake of co-founder and CEO Arkady Nekrasov, and fellow co-founder Natalya Puchkova’s 18.74%. Petrovax owns the rest of its shares. Analysts value the deal at up to $294 million.

The deal would make Abbott the only American company to own production facilities in Russia. DSM analyst Yulia Nechayeva believes that Abbott wants to become localized in the Russian market. DSM says the company annually sells $430 million worth of product in a market worth $30 billion, the paper reports, which doesn’t even qualify for the domestic top 10. Petrovax already manufactures Pfizer’s pneumococcal vaccine.


Yellow Fever Vaccines Available, Yellow Cards Completed

Posted: November 19th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , , | Comments Off on Yellow Fever Vaccines Available, Yellow Cards Completed

Down here in Florida the busy winter season is upon us.  Many of our winter visitors like to go on cruises and safaris that leave from Florida and make stops in exotic places like South America and Africa.  These are beautiful and fascinating destinations but there are also places where Yellow Fever, in addition to other diseases, is endemic.  Many African countries require proof of Yellow Fever vaccination and even some of the cruise lines are requiring Yellow Fever vaccination in order to board their ships.

 

Gelbfieber in Südamerika 2009. Yellow fever in...

Yellow fever in South America in 2009. (Photo credit: Wikipedia)

 

English: Yellow fever map CDC

Yellow fever map CDC (Photo credit: Wikipedia)

 

 

 

Passport Health of Sarasota-Bradenton stocked additional Yellow Fever vaccine to meet the expected demand.  We have Yellow Fever vaccines.  Appointments are appreciated but walk-ins are welcome.  Our clients find our convenient, well-health offices to be very comfortable places to receive vaccines.

Passport Health of Sarasota-Bradenton also prepares Yellow Cards for our clients.  The Yellow Card is a written record of all vaccines a patient has received.  Some countries require to see the Yellow Card before they allow a visitor to enter.  Cruise lines are doing the same now with Yellow Cards and Yellow Fever.

 

English: Detail of an International Certificat...

(Photo credit: Wikipedia)

For all those travelers out there, please be sure that before you visit any destination outside the US and especially in the third world, that you see a travel health specialist.  These professionals will arm you with all the latest health information regarding your destination and should offer vaccines as well as general well-health products.

Safe travels!


Why Do We Vaccinate?

Posted: November 15th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , | Comments Off on Why Do We Vaccinate?

The modern practice of vaccination began with Edward Jenner in 1796, when he inoculated an 8-year-old boy with pus from a cowpox sore, protecting the child against the devastating disease smallpox. For many years, vaccines were associated with the prevention of infectious diseases, but gradually, research began to harness the activity of the immune system to prevent disease as well as treat it, starting in the field of oncology.

The first cancer vaccines to reach the market were Oncophage from Antigenics (now Agenus), which gained approval in Russia in 2008 for the treatment of kidney cancer, and Dendreon’s (Provenge), which gained FDA approval in 2010 for the treatment of metastatic hormone-refractory prostate cancer. Provenge’s complex production process, requiring preparation of an individual vaccine for each patient, has perhaps contributed to its lack of uptake, and most of the cancer vaccines in development are off-the-shelf rather than produced for each patient, and are tailored to groups of patients rather than individuals.

Following along behind therapeutic cancer vaccines are virally targeted therapeutic vaccines, such as those against HIV, and vaccines that cross the boundary between infectious diseases and cancer–the HPV-targeted vaccines for very early-stage cervical cancer and precancerous lesions.


More Influenza Vaccine Available as Flu Season Approaches

Posted: November 13th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , | Comments Off on More Influenza Vaccine Available as Flu Season Approaches

As flu season approaches, vaccines companies are working against the odds to market their influenza vaccines. Last year, the overall U.S. vaccination rate was about 42%–a far cry from the target rates of 80% for people ages 6 months to 65 years and 90% for those older than 65.

Vaccination rates ran the gamut in the 2011-2012 influenza season. For children between 6 months and 23 months, it was 75%, while just over a third of adolescents received the jab, according to the CDC. About 39% of adults were vaccinated, Reuters reports.

This year, a total of 135 million doses of influenza vaccine will be on hand, the nonprofit National Foundation for Infectious Diseases said. As of Sept. 14, more than 85 million doses of the vaccine had been distributed.

“When it comes to flu, we can’t look to the past to predict the future,” Howard Koh, assistant health secretary at the Department of Health and Human Services, said in a news conference, as quoted by Reuters.

FDA green-lighted influenza vaccines from all 6 manufacturers licensed to produce and distribute in the U.S. back in August. This year’s dose includes one strain in common with last year’s and two new ones. But judging by vaccination rates from the previous flu season, the manufactuerers–CSL, GlaxosmithKline, ID Biomedical, AstraZeneca’s MedImmune, Novartis and Sanofi Pasteur–will all be hoping for a change of pace. Factors preventing people from getting the shot include fear that they will get sick from the vaccine, cost and lack of awareness.


Vaccine Demand, Production Increase in India

Posted: November 8th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , | Comments Off on Vaccine Demand, Production Increase in India

Anticipating a sizable shift in India‘s vaccine industry landscape, a new report estimates that the country’s vaccine production sector will likely expand to an estimated $871 million by 2016. Compare that with 2011’s value of $350 million.

Global Business Intelligence Research forecasts the Indian vaccine market will grow 20% a year for the next four years. New research into cancer vaccines and fears of bioterrorism and severe acute respiratory syndrome (SARS) are sparking the rise in production.

In recent years, Indiahas emerged as a major vaccine producer, aiming efforts on geographical regions where vaccines are not funded by the United Nations or charitable organizations. Such a focus meant exports made up 65% of the Indian vaccines market last year.


Malaria Vaccine Development Advances

Posted: November 6th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , | Comments Off on Malaria Vaccine Development Advances

GenVec inked a $3.5 million agreement with the Naval Medical Research Center o support malaria vaccine development.

The Gaithersburg, MD-based company will produce supplies of its vaccine for use in clinical trials.  The company retains the right to commercialize the product.  The NMRC will assess the safety and efficacy of the vaccines in a clinical challenge model it developed with Walter Reed Army Institute of Research malaria vaccine programs.  Those programs are now unified as the U.S. Military Vaccine Program.

NMRC and WRAIR tested out GenVec’s candidate in April 2010 in a Phase I trial.  The data from the trial indicated the vaccine is safe, “causing minimal local or systemic reactions and no serious vaccine-related adverse reactions,” according to GenVec’s statement.  And four out of 15 volunteers inoculated with the vaccine showed a complete absence of parasites in the blood.